Diosmin Tablets

600 mg


For the use of a Registered Medical Practitioner or a Hospital or a Institution only. 

Diosmin Tablets

DIOSMIN  TABLETS (Diosmin) is vascular-protecting agent. Chemically, Diosmin is 7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one. The molecular formula is C28H32O15 and molecular weight is 608.54. 


Its structural formula is :


           Diosmin Tablets


DIOSMIN  TABLETS are orange coloured, biconvex, film coated tablets with break line on one side. 

Each film coated  tablet contains :
Diosmin USP                                                     600 mg
Excipients                                                            q.s.
Colours : Titanium Dioxide B.P., Tartrazine, Sunset Yellow

Diosmin’s mechanisms of action include improvement of venous tone, increased lymphatic drainage, protection of capillary bed microcirculation, inhibition of inflammatory reactions, and reduced capillary permeability. Certain flavonoids, including diosmin, are potent inhibitors of prostaglandin E2 (PGE2) and thromboxane A2 (TxA2) as well as being inhibitors of leucocyte activation, migration, and adhesion. Diosmin causes a significant decrease in plasma levels of endothelial adhesion molecules and reduces neutrophil activation, thus providing protection against microcirculatory damage.

Pharmacokinetic investigations have shown diosmin is rapidly transformed by intestinal flora to its aglycone form, Diosmetin. Diosmetin is absorbed and rapidly distributed throughout the body with a plasma half-life of 26-43 hours. Diosmetin is degraded to phenolic acids or their glycine-conjugated derivatives and eliminated through the urine. Diosmin or diosmetin not absorbed is eliminated in the faeces.

DIOSMIN  TABLETS  are  indicated for :
•  Treatment of symptoms related to venolymphatic insufficiency (heavy legs, pain, early morning restless legs, varicosis, oedema , swelling ), 
•  Treatment of functional symptoms related to acute haemorrhoidal attack. 
•  Treatment of Chronic Venous insufficiency (CVI).
•  Capillary fragility. 


Administration : 
DIOSMIN  TABLETS are for oral administration only. 

Dosage : 
•  Usual dosage : 2 tablets daily in two divided doses, midday and evening at meal times. 
•  Acute haemorrhoidal attack : 6 tablets per day for the first 4 days, then 4 tablets per day for  3 days. 
•  For maintenance in the haemorrhoid illness : 2 tablets to the day. 

Known hypersensitivity to Diosmin or to any of the excipients. 

DIOSMIN  TABLETS contains lactose which is contra-indicated in patients with galactosaemia, the glucose-galactose malabsorption  syndrome, or lactase deficiency.


Acute haemorrhoidal attack :
Administration of this medicine is no substitute for the specific treatment of other haemorrhoidal disorders. The treatment must be short-term. If the symptoms do not disappear rapidly, proctological examination should be performed and the treatment reviewed. 

The tablet contains “tartrazine” colour which may cause allergic reactions, including bronchial asthma, especially in patients who are allergic to the acetyl salicylic acid.

DIOSMIN  TABLETS should be used cautiously in diabetic patients.


Pregnancy : 
Animal studies showed no teratogenic effect. In the absence of teratogenic effects in animals, malformation in humans is not expected. Indeed, the substance responsible for malformations in the human species was revealed in animals during studies conducted on the two species. In the clinic, no malformations or particular foetal toxicity have appeared to date. However, the outcome of pregnancies exposed to diosmin is insufficient to exclude all risk. Consequently, the necessity of this medicine must be considered during pregnancy.

Nursing Mothers : 
In the absence of data concerning excretion into breast milk, breast feeding is not recommended during treatment. 

Diosmin can cause a decrease in RBC aggregation and blood viscosity. There are no documented cases of adverse interactions between diosmin and prescription medications, but caution should be taken when combining diosmin with aspirin or other blood-thinning medications.  Data suggest that diosmin has an inhibitory effect on cytochrome P450-mediated metabolism in healthy volunteers, which may alter the pharmacokinetics of drugs taken concomitantly. Patients given metronidazole after nine days of  pretreatment with 450 mg diosmin demonstrated changes in serum concentrations of metronidazole, as well as changes in urinary concentrations of metronidazole and its metabolites compared to control . 


Commonly reported adverse events included gastrointestinal disturbances and headaches; these were generally mild in severity and did not usually result in patients discontinuing participation in the study. The following adverse events (and approximate percentages) were reported in some clinical trials but their frequency did not differ from placebo : rash (1 %), cramping in lower limb (2 %), phlebitis (2 %), venous thrombosis (4 %), and skin changes around existing ulcer, swelling of the extremities and body rash (1.6 %). 

Dyspepsia, or non-specific mild stomach upset, occurred in up to 7 % of subjects taking diosmin at various doses and was seen with approximately twice the frequency seen in the placebo groups. Rare adverse events include inguinal pain, cystitis, asthenia, metrorrhagia and menometrorrhagia. In clinical trials, the incidence of adverse events in elderly populations (≥ 70 years of age) was not significantly different from that in younger populations nor were adverse events higher in patients with concomitant hypertension, atherosclerosis, diabetes, Neurologic/psychiatric disease or alcoholism.
Not Applicable.
Store below 30°C (86°F), protected from moisture and light.
Do not refrigerate.
24 months from date of manufacture.
DIOSMIN  TABLETS  contains  Diosmin  USP 600 mg .
3 Blisters of 10 Tablets per Box.
Disclaimer : For the use of a Registered Medical Practitioner or a Hospital or a Institution only. Also it is not intended to be used by healthcare professionals or patients for the purpose of prescribing or administering these products. Questions regarding the complete and current content of product labeling / specification / presentation should be directed to SGPharma.
File Size
204.58 KB